Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Kalydeco Ivacaftor Cystic Fibrosis, CFTR gating mutations List with criteria/condition Complete
Kalydeco Ivacaftor Cystic fibrosis, R117H CFTR gating mutation List with criteria/condition Complete
Kanuma sebelipase alfa Lysosomal acid lipase deficiency Reimburse with clinical criteria and/or conditions Complete
Kazano Alogliptin plus metformin Diabetes mellitus, type 2 Do not list Complete
Kerendia finerenone Chronic kidney disease Reimburse with clinical criteria and/or conditions Complete
Kesimpta ofatumumab Multiple Sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete
Kevzara sarilumab Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab classical Hodgkin Lymphoma (cHL) Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab For locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Nonsquamous NSCLC Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab MUC First line Do not reimburse Complete
Keytruda Pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Squamous NSCLC Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Gastrointestinal Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Keytruda pembrolizumab Colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Classical Hodgkin lymphoma Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Renal cell carcinoma, adjuvant Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab recurrent, or metastatic cervical cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Primary mediastinal B-cell lymphoma Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Keytruda pembrolizumab Non-Small Cell Lung Cancer, neoadjuvant Active
Keytruda pembrolizumab advanced or metastatic
malignant pleural mesothelioma (MPM)
Pending